"False"
Umeå universitet
printicon
Huvudmenyn dold.

Nils-Olof Bengtsson

Kontakt

E-post
NilsOlof.Bengtsson@vll.se
Telefon

Verksam vid

Anknytning
Anknuten som läkare till Institutionen för strålningsvetenskaper Enhet: Onkologi
Plats
27C, Målpunkt QC11, Norrlands universitetssjukhus Umeå universitet, 901 87 Umeå
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Acta Oncologica, Vol. 56, (4) : 614-617
Rosell, Johan; Nordenskjold, Bo; Bengtsson, Nils-Olof; et al.
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
Breast Cancer Research and Treatment, New York: Springer 2013, Vol. 138, (2) : 467-473
Rosell, Johan; Nordenskjold, Bo; Bengtsson, Nils-Olof; et al.
The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a european perspective
Value in Health, Vol. 14, (3) : A173-A173
Chadda, S.; Larkin, M.; Jones, C.; et al.
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
Acta Oncologica, Informa Healthcare 2011, Vol. 50, (3) : 329-337
Edlund, Per; Ahlgren, Johan; Bjerre, Karsten; et al.
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Acta Oncologica, Vol. 50, (1) : 35-41
Margolin, Sara; Bengtsson, Nils-Olof; Carlsson, Lena; et al.
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden
Radiotherapy and Oncology, Amsterdam: Elsevier 2011, Vol. 100, (2) : 167-175
McGale, Paul; Darby, Sarah C.; Hall, Per; et al.
Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
British Journal of Cancer, Nature Publishing Group 2011, Vol. 104, (6) : 899-902
Rosell, Johan; Nordenskjöld, B; Bengtsson, Nils-Olof; et al.
The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Acta oncologica (Stockholm, Sweden), Vol. 48, (8) : 1137-1143
Sjöström-Mattson, Johanna; Von Boguslawski, Kristina; Bengtsson, Nils-Olof; et al.
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
J Clin Oncol, Vol. 24, (31) : 4956-4962
Ejlertsen, Bent; Mouridsen, Henning T; Jensen, Maj-Britt; et al.
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
Acta Oncol, Vol. 45, (5) : 590-596
Villman, Kenneth; Sjöström, Johanna; Heikkilä, Reino; et al.
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
The Lancet, Vol. 366, (9503) : 2087-2106
Early Breast Cancer Trialists' Collaborative Group, EBCTCG; Bengtsson, Nils-Olof; Jonsson, Håkan; et al.
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial
J Natl Cancer Inst, Vol. 97, (21) : 1609-1610
Nordenskjöld, Bo; Rosell, Johan; Rutqvist, Lars-Erik; et al.
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
Br J Cancer, Vol. 90, (12) : 2344-2348
Carlsson, J; Nordgren, H; Sjöström, J; et al.
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
British Journal of Cancer, London: Nature Publishing Group 2004, Vol. 90, (10) : 1942-1948
Stendahl, M; Kronblad, Å; Rydén, L; et al.
Visa publikationer i DiVA